TO SPEND OR NOT TO SPEND: Investing For Launch Success As An Emerging Company
Thought Leadership in Association with Syneos Health
Thought Leadership
In the increasingly complex world of biopharmaceutical commercialization, executives at emerging companies are often faced with the need to understand what levels of spend are appropriate for successfully launching a product. Many clinical-stage companies find themselves either underfunding launches and underperforming in the market, or overfunding launches and incurring costs that do not add incremental value to commercial success. And while every company is different, and every launch is different, all face the same question: What is the threshold of commercial spend needed to increase the probability of a successful product launch?
Candid conversations with C-suite leaders.
Thought Leadership